カテゴリー： LP Information, 世界, 医療/バイオ

世界の血管内皮増殖因子阻害剤市場予測 2021年-2026年

【英語タイトル】Global Vascular Endothelial Growth Factor Inhibitor Market Growth 2021-2026

LP Informationが出版した調査資料（LPI21MY9680）・商品コード：LPI21MY9680
・発行会社（調査会社）：LP Information
・発行日：2021年5月（※2024年版があります。お問い合わせください）
・ページ数：161
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥541,680見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥812,520見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,083,360見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
LPインフォメーション社の「血管内皮増殖因子阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、経口薬、注射など、用途別には、病院、外来手術センター、がん研究所などにセグメント区分してまとめました。血管内皮増殖因子阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・血管内皮増殖因子阻害剤の世界市場概要（サマリー）
・血管内皮増殖因子阻害剤の企業別販売量・売上
・血管内皮増殖因子阻害剤の企業別市場シェア
・血管内皮増殖因子阻害剤の世界市場規模 2016年-2021年：種類別（経口薬、注射）
・血管内皮増殖因子阻害剤の世界市場規模 2016年-2021年：用途別（病院、外来手術センター、がん研究所）
・血管内皮増殖因子阻害剤の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど）
・血管内皮増殖因子阻害剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）
・血管内皮増殖因子阻害剤のヨーロッパ市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・血管内皮増殖因子阻害剤の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）
・血管内皮増殖因子阻害剤市場の成長要因・課題・動向
・血管内皮増殖因子阻害剤の世界市場予測 2021年-2026年
・血管内皮増殖因子阻害剤の南北アメリカ市場予測（アメリカ、カナダ、メキシコなど）
・血管内皮増殖因子阻害剤のアジア市場予測（日本、中国、韓国、インド、東南アジアなど）
・血管内皮増殖因子阻害剤のヨーロッパ市場予測（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・血管内皮増殖因子阻害剤の中東・アフリカ市場予測（エジプト、南アフリカ、トルコ、GCC諸国など）
・血管内皮増殖因子阻害剤の世界市場予測：種類別（経口薬、注射）
・血管内皮増殖因子阻害剤の世界市場予測：用途別（病院、外来手術センター、がん研究所）
・主要企業分析
【レポートの概要】

According to this latest study, the 2020 growth of Vascular Endothelial Growth Factor Inhibitor will have significant change from previous year. By the most conservative estimates of global Vascular Endothelial Growth Factor Inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Vascular Endothelial Growth Factor Inhibitor market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Vascular Endothelial Growth Factor Inhibitor market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Oral Medications
Injections

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Pfizer
Novartis
AstraZeneca
Bayer Healthcare
Merck
Genetech
Eli Lilly
Sanofi Aventis
GlaxoSmithKline
Bristol-Myer Squibb
Boehringer Ingelheim

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Vascular Endothelial Growth Factor Inhibitor Consumption 2016-2026
2.1.2 Vascular Endothelial Growth Factor Inhibitor Consumption CAGR by Region
2.2 Vascular Endothelial Growth Factor Inhibitor Segment by Type
2.2.1 Oral Medications
2.2.2 Injections
2.3 Vascular Endothelial Growth Factor Inhibitor Sales by Type
2.3.1 Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
2.3.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue and Market Share by Type (2016-2021)
2.3.3 Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Type (2016-2021)
2.4 Vascular Endothelial Growth Factor Inhibitor Segment by Application
2.4.1 Hospitals
2.4.2 Ambulatory Surgical Centers
2.4.3 Cancer Research Institutes
2.5 Vascular Endothelial Growth Factor Inhibitor Sales by Application
2.5.1 Global Vascular Endothelial Growth Factor Inhibitor Sale Market Share by Application (2016-2021)
2.5.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue and Market Share by Application (2016-2021)
2.5.3 Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Application (2016-2021)

3 Global Vascular Endothelial Growth Factor Inhibitor by Company
3.1 Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Company
3.1.1 Global Vascular Endothelial Growth Factor Inhibitor Sales by Company (2019-2021)
3.1.2 Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Company (2019-2021)
3.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Company
3.2.1 Global Vascular Endothelial Growth Factor Inhibitor Revenue by Company (2019-2021)
3.2.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Company (2019-2021)
3.3 Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Company
3.4 Global Manufacturers Vascular Endothelial Growth Factor Inhibitor Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vascular Endothelial Growth Factor Inhibitor Product Location Distribution
3.4.2 Players Vascular Endothelial Growth Factor Inhibitor Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Vascular Endothelial Growth Factor Inhibitor by Region
4.1 Global Vascular Endothelial Growth Factor Inhibitor by Region
4.1.1 Global Vascular Endothelial Growth Factor Inhibitor Sales by Region
4.1.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue by Region
4.2 Americas Vascular Endothelial Growth Factor Inhibitor Sales Growth
4.3 APAC Vascular Endothelial Growth Factor Inhibitor Sales Growth
4.4 Europe Vascular Endothelial Growth Factor Inhibitor Sales Growth
4.5 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Growth

5 Americas
5.1 Americas Vascular Endothelial Growth Factor Inhibitor Sales by Country
5.1.1 Americas Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021)
5.1.2 Americas Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021)
5.2 Americas Vascular Endothelial Growth Factor Inhibitor Sales by Type
5.3 Americas Vascular Endothelial Growth Factor Inhibitor Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Vascular Endothelial Growth Factor Inhibitor Sales by Region
6.1.1 APAC Vascular Endothelial Growth Factor Inhibitor Sales by Region (2016-2021)
6.1.2 APAC Vascular Endothelial Growth Factor Inhibitor Revenue by Region (2016-2021)
6.2 APAC Vascular Endothelial Growth Factor Inhibitor Sales by Type
6.3 APAC Vascular Endothelial Growth Factor Inhibitor Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Vascular Endothelial Growth Factor Inhibitor by Country
7.1.1 Europe Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021)
7.1.2 Europe Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021)
7.2 Europe Vascular Endothelial Growth Factor Inhibitor Sales by Type
7.3 Europe Vascular Endothelial Growth Factor Inhibitor Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor by Country
8.1.1 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021)
8.1.2 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021)
8.2 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Type
8.3 Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Vascular Endothelial Growth Factor Inhibitor Distributors
10.3 Vascular Endothelial Growth Factor Inhibitor Customer

11 Global Vascular Endothelial Growth Factor Inhibitor Market Forecast
11.1 Global Vascular Endothelial Growth Factor Inhibitor Forecast by Region
11.1.1 Global Vascular Endothelial Growth Factor Inhibitor Forecast by Regions (2021-2026)
11.2.2 Global Vascular Endothelial Growth Factor Inhibitor Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Vascular Endothelial Growth Factor Inhibitor Forecast by Type
11.7 Global Vascular Endothelial Growth Factor Inhibitor Forecast by Application

12 Key Players Analysis
12.1 Pfizer
12.1.1 Pfizer Pfizer Company Information
12.1.2 Pfizer Vascular Endothelial Growth Factor Inhibitor Product Offered
12.1.3 Pfizer Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Pfizer Main Business Overview
12.1.5 Pfizer Latest Developments
12.2 Novartis
12.2.1 Novartis Company Information
12.2.2 Novartis Vascular Endothelial Growth Factor Inhibitor Product Offered
12.2.3 Novartis Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Novartis Main Business Overview
12.2.5 Novartis Latest Developments
12.3 AstraZeneca
12.3.1 AstraZeneca Company Information
12.3.2 AstraZeneca Vascular Endothelial Growth Factor Inhibitor Product Offered
12.3.3 AstraZeneca Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 AstraZeneca Main Business Overview
12.3.5 AstraZeneca Latest Developments
12.4 Bayer Healthcare
12.4.1 Bayer Healthcare Company Information
12.4.2 Bayer Healthcare Vascular Endothelial Growth Factor Inhibitor Product Offered
12.4.3 Bayer Healthcare Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Bayer Healthcare Main Business Overview
12.4.5 Bayer Healthcare Latest Developments
12.5 Merck
12.5.1 Merck Company Information
12.5.2 Merck Vascular Endothelial Growth Factor Inhibitor Product Offered
12.5.3 Merck Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Merck Main Business Overview
12.5.5 Merck Latest Developments
12.6 Genetech
12.6.1 Genetech Company Information
12.6.2 Genetech Vascular Endothelial Growth Factor Inhibitor Product Offered
12.6.3 Genetech Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Genetech Main Business Overview
12.6.5 Genetech Latest Developments
12.7 Eli Lilly
12.7.1 Eli Lilly Company Information
12.7.2 Eli Lilly Vascular Endothelial Growth Factor Inhibitor Product Offered
12.7.3 Eli Lilly Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Eli Lilly Main Business Overview
12.7.5 Eli Lilly Latest Developments
12.8 Sanofi Aventis
12.8.1 Sanofi Aventis Company Information
12.8.2 Sanofi Aventis Vascular Endothelial Growth Factor Inhibitor Product Offered
12.8.3 Sanofi Aventis Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Sanofi Aventis Main Business Overview
12.8.5 Sanofi Aventis Latest Developments
12.9 GlaxoSmithKline
12.9.1 GlaxoSmithKline Company Information
12.9.2 GlaxoSmithKline Vascular Endothelial Growth Factor Inhibitor Product Offered
12.9.3 GlaxoSmithKline Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 GlaxoSmithKline Main Business Overview
12.9.5 GlaxoSmithKline Latest Developments
12.10 Bristol-Myer Squibb
12.10.1 Bristol-Myer Squibb Company Information
12.10.2 Bristol-Myer Squibb Vascular Endothelial Growth Factor Inhibitor Product Offered
12.10.3 Bristol-Myer Squibb Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 Bristol-Myer Squibb Main Business Overview
12.10.5 Bristol-Myer Squibb Latest Developments
12.11 Boehringer Ingelheim
12.11.1 Boehringer Ingelheim Company Information
12.11.2 Boehringer Ingelheim Vascular Endothelial Growth Factor Inhibitor Product Offered
12.11.3 Boehringer Ingelheim Vascular Endothelial Growth Factor Inhibitor Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 Boehringer Ingelheim Main Business Overview
12.11.5 Boehringer Ingelheim Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Vascular Endothelial Growth Factor Inhibitor Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Oral Medications
Table 3. Major Players of Injections
Table 4. Global Vascular Endothelial Growth Factor Inhibitor Sales by Type (2016-2021) & (K Units)
Table 5. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
Table 6. Global Vascular Endothelial Growth Factor Inhibitor Revenue by Type (2016-2021) & ($ million)
Table 7. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Type (2016-2021)
Table 8. Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Type (2016-2021)
Table 9. Global Vascular Endothelial Growth Factor Inhibitor Sales by Application (2016-2021) & (K Units)
Table 10. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Table 11. Global Vascular Endothelial Growth Factor Inhibitor Value by Application (2016-2021)
Table 12. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Application (2016-2021)
Table 13. Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Application (2016-2021)
Table 14. Global Vascular Endothelial Growth Factor Inhibitor Sales by Company (2019-2021) & (K Units)
Table 15. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Company (2019-2021)
Table 16. Global Vascular Endothelial Growth Factor Inhibitor Revenue by Company (2019-2021) ($ Millions)
Table 17. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Company (2019-2021)
Table 18. Global Vascular Endothelial Growth Factor Inhibitor Sale Price by Company (2019-2021)
Table 19. Key Manufacturers Vascular Endothelial Growth Factor Inhibitor Producing Area Distribution and Sales Area
Table 20. Players Vascular Endothelial Growth Factor Inhibitor Products Offered
Table 21. Vascular Endothelial Growth Factor Inhibitor Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 22. New Products and Potential Entrants
Table 23. Mergers & Acquisitions, Expansion
Table 24. Global Vascular Endothelial Growth Factor Inhibitor Sales by Region (2016-2021) (K Units)
Table 25. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Region (2016-2021)
Table 26. Global Vascular Endothelial Growth Factor Inhibitor Revenue by Region (2016-2021) & ($ Millions)
Table 27. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Region (2016-2021)
Table 28. Americas Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021) & (K Units)
Table 29. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country (2016-2021)
Table 30. Americas Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 31. Americas Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country (2016-2021)
Table 32. Americas Vascular Endothelial Growth Factor Inhibitor Sales by Type (2016-2021) & (K Units)
Table 33. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
Table 34. Americas Vascular Endothelial Growth Factor Inhibitor Sales by Application (2016-2021) & (K Units)
Table 35. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Table 36. APAC Vascular Endothelial Growth Factor Inhibitor Sales by Region (2016-2021) & (K Units)
Table 37. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Region (2016-2021)
Table 38. APAC Vascular Endothelial Growth Factor Inhibitor Revenue by Region (2016-2021) & ($ Millions)
Table 39. APAC Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Region (2016-2021)
Table 40. APAC Vascular Endothelial Growth Factor Inhibitor Sales by Type (2016-2021) & (K Units)
Table 41. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
Table 42. APAC Vascular Endothelial Growth Factor Inhibitor Sales by Application (2016-2021) & (K Units)
Table 43. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Table 44. Europe Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021) & (K Units)
Table 45. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country (2016-2021)
Table 46. Europe Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 47. Europe Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country (2016-2021)
Table 48. Europe Vascular Endothelial Growth Factor Inhibitor Sales by Type (2016-2021) & (K Units)
Table 49. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
Table 50. Europe Vascular Endothelial Growth Factor Inhibitor Sales by Application (2016-2021) & (K Units)
Table 51. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Table 52. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Country (2016-2021) & (K Units)
Table 53. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country (2016-2021)
Table 54. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Revenue by Country (2016-2021) & ($ Millions)
Table 55. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country (2016-2021)
Table 56. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Type (2016-2021) & (K Units)
Table 57. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type (2016-2021)
Table 58. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales by Application (2016-2021) & (K Units)
Table 59. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Table 60. Global Vascular Endothelial Growth Factor Inhibitor Sales Forecast by Type (2021-2026) & (K Units)
Table 61. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share Forecast by Type (2021-2026)
Table 62. Global Vascular Endothelial Growth Factor Inhibitor Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 63. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share Forecast by Type (2021-2026)
Table 64. Global Vascular Endothelial Growth Factor Inhibitor Sales Forecast by Application (2021-2026) & (K Units)
Table 65. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share Forecast by Application (2021-2026)
Table 66. Global Vascular Endothelial Growth Factor Inhibitor Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 67. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share Forecast by Application (2021-2026)
Table 68. Pfizer Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 69. Pfizer Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 70. Pfizer Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 71. Pfizer Main Business
Table 72. Pfizer Latest Developments
Table 73. Novartis Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 74. Novartis Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 75. Novartis Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 76. Novartis Main Business
Table 77. Novartis Latest Developments
Table 78. AstraZeneca Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 80. AstraZeneca Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Bayer Healthcare Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 84. Bayer Healthcare Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 85. Bayer Healthcare Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 86. Bayer Healthcare Main Business
Table 87. Bayer Healthcare Latest Developments
Table 88. Merck Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 89. Merck Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 90. Merck Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 91. Merck Main Business
Table 92. Merck Latest Developments
Table 93. Genetech Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 94. Genetech Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 95. Genetech Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 96. Genetech Main Business
Table 97. Genetech Latest Developments
Table 98. Eli Lilly Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 99. Eli Lilly Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 100. Eli Lilly Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 101. Eli Lilly Main Business
Table 102. Eli Lilly Latest Developments
Table 103. Sanofi Aventis Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 104. Sanofi Aventis Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 105. Sanofi Aventis Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 106. Sanofi Aventis Main Business
Table 107. Sanofi Aventis Latest Developments
Table 108. GlaxoSmithKline Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 109. GlaxoSmithKline Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 110. GlaxoSmithKline Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 111. GlaxoSmithKline Main Business
Table 112. GlaxoSmithKline Latest Developments
Table 113. Bristol-Myer Squibb Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 114. Bristol-Myer Squibb Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 115. Bristol-Myer Squibb Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 116. Bristol-Myer Squibb Main Business
Table 117. Bristol-Myer Squibb Latest Developments
Table 118. Boehringer Ingelheim Basic Information, Vascular Endothelial Growth Factor Inhibitor Manufacturing Base, Sales Area and Its Competitors
Table 119. Boehringer Ingelheim Vascular Endothelial Growth Factor Inhibitor Product Offered
Table 120. Boehringer Ingelheim Vascular Endothelial Growth Factor Inhibitor Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 121. Boehringer Ingelheim Main Business
Table 122. Boehringer Ingelheim Latest Developments
List of Figures
Figure 1. Picture of Vascular Endothelial Growth Factor Inhibitor
Figure 2. Vascular Endothelial Growth Factor Inhibitor Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vascular Endothelial Growth Factor Inhibitor Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Vascular Endothelial Growth Factor Inhibitor Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Vascular Endothelial Growth Factor Inhibitor Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Oral Medications
Figure 10. Product Picture of Injections
Figure 11. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type in 2020
Figure 12. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Type (2016-2021)
Figure 13. Vascular Endothelial Growth Factor Inhibitor Consumed in Hospitals
Figure 14. Global Vascular Endothelial Growth Factor Inhibitor Market: Hospitals (2016-2021) & (K Units)
Figure 15. Vascular Endothelial Growth Factor Inhibitor Consumed in Ambulatory Surgical Centers
Figure 16. Global Vascular Endothelial Growth Factor Inhibitor Market: Ambulatory Surgical Centers (2016-2021) & (K Units)
Figure 17. Vascular Endothelial Growth Factor Inhibitor Consumed in Cancer Research Institutes
Figure 18. Global Vascular Endothelial Growth Factor Inhibitor Market: Cancer Research Institutes (2016-2021) & (K Units)
Figure 19. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application (2016-2021)
Figure 20. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Application in 2020
Figure 21. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market by Company in 2020 ($ Million)
Figure 22. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Company in 2020
Figure 23. Global Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Regions (2016-2021)
Figure 24. Global Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Region in 2020
Figure 25. Americas Vascular Endothelial Growth Factor Inhibitor Sales 2016-2021 (K Units)
Figure 26. Americas Vascular Endothelial Growth Factor Inhibitor Revenue 2016-2021 ($ Millions)
Figure 27. APAC Vascular Endothelial Growth Factor Inhibitor Sales 2016-2021 (K Units)
Figure 28. APAC Vascular Endothelial Growth Factor Inhibitor Revenue 2016-2021 ($ Millions)
Figure 29. Europe Vascular Endothelial Growth Factor Inhibitor Sales 2016-2021 (K Units)
Figure 30. Europe Vascular Endothelial Growth Factor Inhibitor Revenue 2016-2021 ($ Millions)
Figure 31. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales 2016-2021 (K Units)
Figure 32. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Revenue 2016-2021 ($ Millions)
Figure 33. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country in 2020
Figure 34. Americas Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country in 2020
Figure 35. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type in 2020
Figure 36. Americas Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application in 2020
Figure 37. United States Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 38. Canada Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 39. Mexico Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 40. Brazil Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 41. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Region in 2020
Figure 42. APAC Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Regions in 2020
Figure 43. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type in 2020
Figure 44. APAC Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application in 2020
Figure 45. China Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 46. Japan Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 47. Korea Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 48. Southeast Asia Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 49. India Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 50. Australia Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 51. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country in 2020
Figure 52. Europe Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country in 2020
Figure 53. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type in 2020
Figure 54. Europe Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application in 2020
Figure 55. Germany Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 56. France Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 57. UK Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 58. Italy Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 59. Russia Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 60. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Country in 2020
Figure 61. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Revenue Market Share by Country in 2020
Figure 62. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Type in 2020
Figure 63. Middle East & Africa Vascular Endothelial Growth Factor Inhibitor Sales Market Share by Application in 2020
Figure 64. Egypt Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 65. South Africa Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 66. Israel Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 67. Turkey Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 68. GCC Country Vascular Endothelial Growth Factor Inhibitor Revenue Growth 2016-2021 ($ Millions)
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles


★調査レポート[世界の血管内皮増殖因子阻害剤市場予測 2021年-2026年] (コード：LPI21MY9680)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の血管内皮増殖因子阻害剤市場予測 2021年-2026年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 血管内皮増殖因子(VEGF)阻害剤の世界市場：規模・現状・予測2019-2025
    DATA909X19071 / QYResearch / 2019年11月25日 / ※当調査レポートでは、血管内皮増殖因子(VEGF)阻害剤の世界市場について調査・分析し、血管内皮増殖因子(VEGF)阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤）、用途別（腫瘍学、眼科）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の血管内皮増殖因子(VEGF)阻害剤市場動向 ・主要企業別マーケットシェア ・血管内皮増殖因子(VEGF)阻害剤の種類別市場規模2014-2019 （VEGF-A阻害剤、VEGF-B阻害剤、VEGF-C阻害剤、VEGF-D阻害剤） ・血管内皮増殖因子(VEGF)阻害剤の用途別市場規模2014-2019 （腫瘍学、眼科） ・血管内皮増殖因子(VEGF)阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・血管内皮増殖因子(VEGF)阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模...Vascular endothelial growth factor inhibitors, also known as angiogenesis inhibitors, can prevent the generation of new blood vessels. The vascular endothelial growth factor is a protein that can trigger endothelial cells or pre-existing vessels to form new blood vessels. However, overexpression of vascular endothelial growth factor can generate cancerous cells. In 2018, the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Vascular Endothelial Growth Factor (VEGF) Inhibitors status,...
  • 世界の第XIII因子濃縮物市場予測 2021年-2026年
    LPI21MY9532 / LP Information / 2021年5月 / LPインフォメーション社の「第XIII因子濃縮物の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、1000IU、1600IUなど、用途別には、病院、クリニックなどにセグメント区分してまとめました。第XIII因子濃縮物のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・第XIII因子濃縮物の世界市場概要（サマリー） ・第XIII因子濃縮物の企業別販売量・売上 ・第XIII因子濃縮物の企業別市場シェア ・第XIII因子濃縮物の世界市場規模 2016年-2021年：種類別（1000IU、1600IU） ・第XIII因子濃縮物の世界市場規模 2016年-2021年：用途別（病院、クリニック） ・第XIII因子濃縮物の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・第XIII因子濃縮物のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Factor XIII Concentrate will have significant change from previous year. By the most conservative estimates of global Factor XIII Concentrate market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Factor XIII Concentrate market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Factor XIII Concentrate market by product type,...
  • 世界のフォンウィルブランド因子（組換え）市場予測 2021年-2026年
    LPI21MY9690 / LP Information / 2021年5月 / LPインフォメーション社の「フォンウィルブランド因子（組換え）の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、650IU、 1300IUなど、用途別には、病院、クリニックなどにセグメント区分してまとめました。フォンウィルブランド因子（組換え）のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・フォンウィルブランド因子（組換え）の世界市場概要（サマリー） ・フォンウィルブランド因子（組換え）の企業別販売量・売上 ・フォンウィルブランド因子（組換え）の企業別市場シェア ・フォンウィルブランド因子（組換え）の世界市場規模 2016年-2021年：種類別（650IU、 1300IU） ・フォンウィルブランド因子（組換え）の世界市場規模 2016年-2021年：用途別（病院、クリニック）...According to this latest study, the 2021 growth of von Willebrand Factor (Recombinant) will have significant change from previous year. By the most conservative estimates of global von Willebrand Factor (Recombinant) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the von Willebrand Factor (Recombinant) market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of von Willebrand Factor (Recombinant)...
  • 世界のIDO阻害剤市場予測 2021年-2026年
    LPI21MY9643 / LP Information / 2021年5月 / LPインフォメーション社の「IDO阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、小分子、細胞療法、非公開など、用途別には、がん、アルツハイマー疾患、うつ病、白内障などにセグメント区分してまとめました。IDO阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・IDO阻害剤の世界市場概要（サマリー） ・IDO阻害剤の企業別販売量・売上 ・IDO阻害剤の企業別市場シェア ・IDO阻害剤の世界市場規模 2016年-2021年：種類別（小分子、細胞療法、非公開） ・IDO阻害剤の世界市場規模 2016年-2021年：用途別（がん、アルツハイマー疾患、うつ病、白内障） ・IDO阻害剤の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・IDO阻害剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of IDO inhibitor will have significant change from previous year. By the most conservative estimates of global IDO inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the IDO inhibitor market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of IDO inhibitor market by product type, application, key manufacturers and...
  • 世界のアルファ-1プロテアーゼ阻害剤市場予測 2021年-2026年
    LPI21MY9398 / LP Information / 2021年5月 / LPインフォメーション社の「アルファ-1プロテアーゼ阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、溶液、粉末など、用途別には、病院、クリニックなどにセグメント区分してまとめました。アルファ-1プロテアーゼ阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・アルファ-1プロテアーゼ阻害剤の世界市場概要（サマリー） ・アルファ-1プロテアーゼ阻害剤の企業別販売量・売上 ・アルファ-1プロテアーゼ阻害剤の企業別市場シェア ・アルファ-1プロテアーゼ阻害剤の世界市場規模 2016年-2021年：種類別（溶液、粉末） ・アルファ-1プロテアーゼ阻害剤の世界市場規模 2016年-2021年：用途別（病院、クリニック） ・アルファ-1プロテアーゼ阻害剤の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・アルファ-1プロテアーゼ阻害剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Alpha-1 Proteinase Inhibitor will have significant change from previous year. By the most conservative estimates of global Alpha-1 Proteinase Inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ XX million in 2020. Over the next five years the Alpha-1 Proteinase Inhibitor market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Alpha-1 Proteinase Inhibitor market by product type,...
  • 世界の処方用プロトンポンプ阻害剤市場予測 2021年-2026年
    LPI21MY9554 / LP Information / 2021年5月 / LPインフォメーション社の「処方用プロトンポンプ阻害剤の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ランソプラゾール、パントプラゾール、ラベプラゾール、その他など、用途別には、病院、研究所、その他などにセグメント区分してまとめました。処方用プロトンポンプ阻害剤のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・処方用プロトンポンプ阻害剤の世界市場概要（サマリー） ・処方用プロトンポンプ阻害剤の企業別販売量・売上 ・処方用プロトンポンプ阻害剤の企業別市場シェア ・処方用プロトンポンプ阻害剤の世界市場規模 2016年-2021年：種類別（ランソプラゾール、パントプラゾール、ラベプラゾール、その他） ・処方用プロトンポンプ阻害剤の世界市場規模 2016年-2021年：用途別（病院、研究所、その他） ・処方用プロトンポンプ阻害剤の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・処方用プロトンポンプ阻害剤のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Prescription Proton Pump Inhibitor will have significant change from previous year. By the most conservative estimates of global Prescription Proton Pump Inhibitor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ XX million in 2020. Over the next five years the Prescription Proton Pump Inhibitor market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Prescription Proton Pump Inhibitor...
  • 世界のクリオプレシピテート抗血友病因子市場予測 2021年-2026年
    LPI21MY9496 / LP Information / 2021年5月 / LPインフォメーション社の「クリオプレシピテート抗血友病因子の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、組換え、血漿由来、その他など、用途別には、低フィブリノゲン血症、フォンウィルブランド病、異常フィブリノゲン血症、血友病A、尿毒症、その他などにセグメント区分してまとめました。クリオプレシピテート抗血友病因子のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・クリオプレシピテート抗血友病因子の世界市場概要（サマリー） ・クリオプレシピテート抗血友病因子の企業別販売量・売上 ・クリオプレシピテート抗血友病因子の企業別市場シェア ・クリオプレシピテート抗血友病因子の世界市場規模 2016年-2021年：種類別（組換え、血漿由来、その他） ・クリオプレシピテート抗血友病因子の世界市場規模 2016年-2021年：用途別（低フィブリノゲン血症、フォンウィルブランド病、異常フィブリノゲン血症、血友病A、尿毒症、その他） ・クリオプレシピテート抗血友病因子の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・クリオプレシピテート抗血友病因子のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cryoprecipitated Antihemophilic Factor will have significant change from previous year. By the most conservative estimates of global Cryoprecipitated Antihemophilic Factor market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Cryoprecipitated Antihemophilic Factor market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cryoprecipitated Antihemophilic Factor market by product type,...
  • 世界のAC力率トランスデューサ市場予測 2021年-2026年
    LPI21MY5145 / LP Information / 2021年5月 / LPインフォメーション社の「AC力率トランスデューサの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、単相、二相、多相など、用途別には、工業用、商業用、その他などにセグメント区分してまとめました。AC力率トランスデューサのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・AC力率トランスデューサの世界市場概要（サマリー） ・AC力率トランスデューサの企業別販売量・売上 ・AC力率トランスデューサの企業別市場シェア ・AC力率トランスデューサの世界市場規模 2016年-2021年：種類別（単相、二相、多相） ・AC力率トランスデューサの世界市場規模 2016年-2021年：用途別（工業用、商業用、その他） ・AC力率トランスデューサの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・AC力率トランスデューサのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of AC Power Factor Transducers will have significant change from previous year. By the most conservative estimates of global AC Power Factor Transducers market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the AC Power Factor Transducers market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of AC Power Factor Transducers...
  • 世界の血管グラフトデバイス市場予測 2021年-2026年
    LPI21MY9325 / LP Information / 2021年5月 / LPインフォメーション社の「血管グラフトデバイスの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、大動脈グラフト、透析グラフト、末梢グラフト、血管パッチ、トンネリング＆付属品など、用途別には、病院、専門クリニック、外来外科センター（ASC）などにセグメント区分してまとめました。血管グラフトデバイスのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・血管グラフトデバイスの世界市場概要（サマリー） ・血管グラフトデバイスの企業別販売量・売上 ・血管グラフトデバイスの企業別市場シェア ・血管グラフトデバイスの世界市場規模 2016年-2021年：種類別（大動脈グラフト、透析グラフト、末梢グラフト、血管パッチ、トンネリング＆付属品） ・血管グラフトデバイスの世界市場規模 2016年-2021年：用途別（病院、専門クリニック、外来外科センター（ASC）） ・血管グラフトデバイスの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・血管グラフトデバイスのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Vascular Graft Devices will have significant change from previous year. By the most conservative estimates of global Vascular Graft Devices market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 2234.6 million in 2019. Over the next five years the Vascular Graft Devices market will register a 6.1% CAGR in terms of revenue, the global market size will reach US$ 2827.3 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Vascular Graft Devices market by product type,...
  • 世界の力率トランスデューサー市場予測 2021年-2026年
    LPI21MY4931 / LP Information / 2021年5月 / LPインフォメーション社の「力率トランスデューサーの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、AC力率トランスデューサ、DC力率トランスデューサなど、用途別には、産業用、商業用、その他などにセグメント区分してまとめました。力率トランスデューサーのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・力率トランスデューサーの世界市場概要（サマリー） ・力率トランスデューサーの企業別販売量・売上 ・力率トランスデューサーの企業別市場シェア ・力率トランスデューサーの世界市場規模 2016年-2021年：種類別（AC力率トランスデューサ、DC力率トランスデューサ） ・力率トランスデューサーの世界市場規模 2016年-2021年：用途別（産業用、商業用、その他） ・力率トランスデューサーの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・力率トランスデューサーのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Power Factor Transducers will have significant change from previous year. By the most conservative estimates of global Power Factor Transducers market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Power Factor Transducers market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Power Factor Transducers market by product type,...

    • ◆H&Iグローバルリサーチのお客様（例）◆